Specialist oncology-focused development and commercialisation company has granted an exclusive worldwide licence to Glycart Biotechnology to develop a preclinical antibody for the treatment of cancer
The licensed antibody selectively binds to a cell surface-presented protein that is over-expressed in certain types of cancer including colorectal cancer.
The antibody was originally developed by Cancer Research UK.
Glycart will use its proprietary Glycomab technology to enhance the in vivo efficacy of the antibody.
A research collaboration between CRT, Glycart and the University of Oxford has been established to investigate the potential efficacy of the glyco-engineered antibody in pre-clinical studies Phil L'Huillier, CRT's director of business management, said: "This is a significant step forward in the development of this technology as a therapeutic agent.
"We're very pleased that Glycart is taking this exciting antibody forward and we look forward to the development of a therapeutic that will help treat bowel cancer more efficiently."
